Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: A randomized double-blind study

Página do item simplificado
dc.citation.issue10
dc.citation.volume19
dc.contributor.authorGiraldes, Ana Laura Albertoni [UNIFESP]
dc.contributor.authorSalomão, Reinaldo [UNIFESP]
dc.contributor.authorLeal, Plinio da Cunha [UNIFESP]
dc.contributor.authorBrunialti, Milena Karina Coló [UNIFESP]
dc.contributor.authorSakata, Rioko Kimiko [UNIFESP]
dc.coverageHoboken
dc.date.accessioned2020-07-31T12:47:36Z
dc.date.available2020-07-31T12:47:36Z
dc.date.issued2016
dc.description.abstractAim: Regarding the use of intravenous lidocaine in fibromyalgia, there are no well-controlled studies. This study aimed to evaluate the effect of intravenous lidocaine on pain intensity, clinical manifestations and plasma levels of interleukin (IL)-1, IL-6, and IL-8 in fibromyalgia patients. Methods: In a randomized double-blind study, group 1 patients received 240 mg of lidocaine in 125 mL of saline solution, while group 2 patients received 125 mL of saline, both once a week for 4 weeks (T1, T2, T3 and T4). All patients received amitriptyline. The following were assessed: pain intensity before treatment (T0) and at 1, 2, 3, 4 and 8 weeks after treatmenten
dc.description.abstractclinical manifestationsen
dc.description.abstractthe fibromyalgia impact questionnaire (FIQ) before and at 4 and 8 weeks afteren
dc.description.abstractthe levels of IL 1, 6 and 8 before and at 4 and 8 weeks after treatment. Results: Lower pain intensity was observed in the lidocaine group at T2, with no difference at the other time points. There was a reduction in pain intensity in both groups. The use of paracetamol and tramadol and plasma levels of IL-1, IL-6 and IL-8 did not differ between the groups. Clinical manifestations and side effects did not differ between groups. Conclusions: The combination of 240 mg of intravenous lidocaine (once a week for 4 weeks) with 25 mg of amitriptyline for 8 weeks had no meaningful impact in fibromyalgia patients.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Anesthesia, Sao Paulo, Brazil
dc.description.affiliationUnifespDepartment of Anesthesia, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIDFAPESP: 2011/09807-9
dc.format.extent946-953
dc.identifierhttp://dx.doi.org/10.1111/1756-185X.12904
dc.identifier.citationInternational Journal Of Rheumatic Diseases. Hoboken, v. 19, n. 10, p. 946-953, 2016.
dc.identifier.doi10.1111/1756-185X.12904
dc.identifier.issn1756-1841
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/56924
dc.identifier.wosWOS:000400672400002
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofInternational Journal Of Rheumatic Diseases
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectfibromyalgiaen
dc.subjectinterleukin 1en
dc.subject6en
dc.subject8en
dc.subjectintravenousen
dc.subjectlidocaineen
dc.subjectneurotransmittersen
dc.titleEffect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: A randomized double-blind studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos